tissue damages caused by radiotherapy, and simultaneously stimulate natural immunity of organism, particularly enhancing NK cell activity [16] , so it is one of the best collocations in radiotherapy. Thermotherapy, which contains radiofrequency ablation and hot lavage treatment, can effectively destruct the immune barrier of tumors and immobilize the tertiary structure of proteins, thus retrieving antigens and making exposed tumor antigen more stable. Therefore, thermotherapy can not only cause tumor cell necrosis but also strongly enhance body's antitumor immunity, being the best treatment compatible with biological immunotherapy. Chemotherapy can effectively eliminate tumor load and destroy tumor stroma, but has great toxicity and side effects. Therefore, in order to to avoid systemic toxicity and side effects, it is better to deliver chemotherapeutic drugs locally, use them in a lower dose, or use targeted drugs. Biological immunotherapy represents the core of novel strategy for tumor treatment recently. Deep analysis of body's intrinsic antitumor immune system is the premise and foundation for scientific and rational development of tumor biological immunotherapy.
Biological immunotherapy for solid tumors
Intrinsic antitumor immune system of human body Fig. 1 shows the intrinsic antitumor immune system of human body. Specific antigen of mutant cells, namely tumor antigen, consists of products of mutant genes, abnormal metabolism and glycosylation modification, which can be engulfed by DC cells under normal circumstances. After being processed, tumor antigen can be delivered to B cells, and induce B cells differentiate into plasmacyte, thus leading to the production of specific antibodies. These antibodies can direct NK cells to kill tumor cells selectively, which is the so-called antibody-dependent cell cytotoxicity (ADCC effect) [17] , and can also guide macrophages to phagocytose tumor cells, which is the so-called antibody-dependent cell phagocytosis (ADCP effect) [18] . Meanwhile, the antigens processed by DC cells can induce the production of cytotoxic T lymphocytes (CTL) to selectively kill tumor cells after being directly delivered to T cells. The so-called CAR-T technology is a brand new therapeutic technique through the "mix and match" of T cells and tumor specific antibodies [19] [20] [21] .
NK cells and macrophages are natural immune cells with high activity which do not need direct antigen stimulation, exhibiting powerful killing effect on tumors. NK cells have cytoplasm filled with a variety of active particles, like perforin, granzyme and IFN-gamma that can be quickly released to destroy tumor cells. In contrast, T cells need to be activated by antigens and thus exert a secondary or delayed killing effect on tumor. Tumor immune escape mainly refers to escape from the killing effects of NK cells and macrophages. Escaping occurs in the following two conditions: the encapsulation and camouflage of tumor antigens and the formation of natural barrier by tumor stroma. For instance, tumor cells can inhibit T cell activation through overexpressing its ligand PD-L1 [22] . First of all, tumors have to escape the first line of defense in the occurrence and development, namely the killing effects mediated by NK cells and the phagocytosis mediated by macrophages. Then, they positively fight against T cells and keep T cells in a "disability" state through multiple methods, including expressing ligands for T cell inhibitory receptors, collecting immunosuppressive regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSC), consuming local oxygen, and producing numerous abnormal metabolites. However, a group of T cells that can recognize the tumor cells will develop in this process.
Strategies for activating T cells against solid tumors
Based on the above analyses, T cells have to be activated properly so as to fight with tumors, but without being facilitated for its recognition of tumor cells, which has been demonstrated by the successful application of PD-1 antibodies. Therefore, it is preferred that T cells should be prepared by autologous peripheral blood or tumor-infiltrating lymphocytes (TIL) due to the fact that they have memorized the tumor cells and do not need the antigen presentation by DC cells any more. Researches on DC vaccine have been carried out for many years, and in 2010, the first DC vaccine used for the treatment of prostatic cancer appeared on the market [23] . However, its effectiveness in clinic is not significant, which also proves the viewpoint presented above.
In order to activate T cells properly, it is necessary to understand required signals or conditions for this process. Based on existing achievements, we can make a summary that proper activation of T cells needs four main signals: T cell receptor (TCR) signal, costimulatory signal, inhibitory receptor signal and environmental factor signal (Fig. 2) . For TCR signal, DC cells or APC cells deliver antigen information to T cells, producing TCR aiming at specific tumor antigens through gene rearrangement, which is the first step in anti-tumor T cell activation. Hence, the TCR signal can also be considered as tumor recognition signal. Currently, we can activate TCR via CD3 antibody (OKT3) [24] . This activation is not selective and can activate all T cells sensitized by any antigens. However, if bi-specific antibody is employed by fusing OKT3 with specific antibody aiming at tumor antigen, it may guide T cells to kill tumor cells with excellent specificity [25] . Costimulatory signal is an elaborate regulatory mechanism developed in immune cell evolution, aiming at preventing the "simple and crude" mode of immune cell in response to stimulation, and therefore activating T cell properly. The costimulatory signal give T cells sufficient time to "think" before responding to stimulation and to have "flexible" space for multiple responses to the same stimulation. The most common costimulatory signals contain B7/CD28, CD137/CD137L and Cd40/CD40L [26, 27] . Inhibitory receptor signal is a "brake" signal to prevent the excessive activation of T cells, which plays a key role in balancing cellular immunity [28] . Tumor cells intelligently employ this intrinsic immune regulatory mechanism to inhibit the activation of T cells. In tumor occurrence and development, under the stimulation by tumor antigens, a group of specific T cells are produced that can recognize tumor cells, thus forming TCR recognizing tumor specific antigens. Nonetheless, whether costimulatory signal is properly activated or inhibited needs specific detection. Currently, it is clear that tumor cells can make T cell inactive through expressing the ligands of its inhibitory receptors, like PD-L1 [29] . More importantly, the absence of immune activation factors or the presence of immunosuppressive factors in tumor microenvironment can lead to the loss of environmental factor signal, thus inhibiting T cell activation. In the presence of any signals or under any conditions, the probability of realizing complete activation of T cells is only 25%. This reasonably explains why single application of PD-1 antibody in clinic only gains an effective rate of about 20-30%. For example, according to "Science" report, of 1, 800 melanoma patients treated with PD-1 antibody, only 22% gained satisfactory results [30] . Interestingly, a recent study has found that the efficacy of PD-1 antibody is not only dependent on PD-1 expression, but also requires the presence of CD28 costimulatory molecule [31] . Undoubtedly, such efficacy also needs the presence of TCR signal and environmental factor signal simultaneously.
In accordance with the above analyses, the following methods should be applied to solve the problem of T cell activation. Bispecific antibodies targeting both CD3 molecule and tumor specific antigen could be used to activate TCR signal and to guide T cell to kill tumor in the same time. And blocking antibodies for the inhibitory receptors, such as PD-1 and CTLA-4 antibodies, can be employed to relieve inhibitory signal of T cell activation; alternatively, PD-L1 antibody could also be utilized to block the ligand of inhibitory receptor on the surface of tumor cells [32] [33] [34] . Drugs or biotechnologies are able to provide or strengthen costimulatory signals. CD28 antibody activating CD28 molecule is an important mean to strengthen costimulatory signal. TGN1412, the CD28 superactive antibody developed by German Tegenero AG Pharmaceutical Company, can strongly activate immune cells (mainly referring to T cell) of the body. Significant therapeutic effects have been achieved in animal experiments, including those on primates like monkeys. Nevertheless, TGN1412 administration already resulted in excessive activation of T cells in a clinical trial, with infamous "Elephant man" event as the consequence [35] [36] [37] . Thus, moderate, orderly and controllable activation of immune cells is of great importance in immunotherapy. To achieve this objective, a systematic check on the equilibrium state of different immune cells and on their proliferation and activation capacity is essential, and multiple situations containing dose-response, time-effect, targeting, and compatibility should be considered in medication. Certainly, blocking antibodies of inflammatory factors can be employed to perform precise intervention treatment for "cytokine storm" caused by excessive activation of immune cells (see detailed information in the following section of environment modulatory treatment), so as to prevent immune cells from exhaustion. Our laboratory developed a type of recombinant replication defective adenovirus BB102 carrying three genes B7-1, GM-CSF and P53 [38] . This virus can enhance costimulatory signal required for T cell activation through infecting tumor cells or DC cells. Preclinical study on this virus has already been completed and phase II clinical trials have been documented, making the virus a potential reagent for tumor immunotherapy. Additionally, thalidomide and its second generation drug lenalidomide, well-known as immunoregulatory drugs (IMiD), can activate T cells together with TCR signal in the absence of costimulatory signal, and strengthen T cell activation in the presence of costimulatory signal [39, 40] . Immunomodulatory cytokines like interferons, interleukins and thymosins are required to create a favorable immune microenvironment for T cell activation [41] [42] [43] . Therefore, it is of great significance to stimulate T cells activation in tumor treatments via supplementing these immunomodulatory cytokines at appropriate time, or combining them with other biological drugs, such as antibodies and immune cells. For instance, a very recent study has reported that the combined application of NKTR-214 (PEG modified IL-2) can greatly enhance the antitumor efficiency of PD-1 antibody [44] . Antitumor strategies to enhance the activity and tumor recognition of NK cells NK cell, found in 1973, is also called large granular lymphocyte in early stage because its cytoplasm is full of particles [45] . It can be assumed that NK cells are immune cells that have endocrine functions, because they have the functions of substance storage and rapid release like neuroendocrine cells, such as synapse, pancreatic islet beta cells and adrenocortical cells. A variety of active substances such as granzyme, perforin, IFN-gamma and TNF-alpha are stored in NK cells. When NK cells are stimulated and activated, these particles will be rapidly released, just as the insulin is largely released from beta cells after meals. Similar to endocrine cells, NK cell activity is also governed by neurotransmitter or endocrine hormone. When people are tense and anxious or in a stress state, their bodies will secrete a large amount of glucocorticoids. This stress response can cause a rapid decrease in NK cell activity. For example, brief mental strain can dramatically reduce NK cell activity in killing tumor cells, and 3 days are the minimum for the activity to return normal level. Prolonged mental depression or tension requires even a longer time [46] . Therefore, the NK cell activity can be improved via providing an enriched environment, keeping cheerful mood or controlling patient's mood by medication, such as antidepressant and nerve stimulant. NK cells with strong activity, together with macrophages, form the first line of immune barrier to prevent tumorigenesis. In tumor occurrence and development, tumor cells can disguise themselves through wrapping or hiding tumor antigens so as to escape the attack from NK cells in early stage. When tumor microenvironment establishes, NK cells cannot be fully activated under the influences of various factors. Consequently, two major problems on NK cells need to be solved in tumor treatment: promoting the capability of NK cells to recognize tumor cells and improving body's internal environment to increase the activity of NK cells.
In detail, methods should include the following aspects. Allogeneic NK cells, such as cord blood NK cells, relative or unrelated individual NK cells should be used to solve the problem that autologous NK cells only have low activity or cannot effectively recognize autologous tumor. Epigenetic drugs or physiotherapies like radiotherapy and thermotherapy should be applied to alter tumor phenotype, exposing its antigen and promoting the ability of NK cells to identify and kill tumor cells. Intriguingly, these epigenetic or DNA-binding drugs could also stimulate immune responses that mimic those induced by viral pathogens through Toll-like receptors [47, 48] . NK cells should be used in combination with antitumor specific antibodies, such as Erbitux, Herceptin and Mabthera, to specifically kill corresponding tumor cells through antibody-dependent cell cytotoxicity (ADCC effect). Drugs or reagents are used to enrich NK cells in tumor local tissue by changing their migratory pathway, and then guide them to kill tumor cells in an indirect way. The distribution of NK cells in different tissues and organs are regulated by different signal molecules [49, 50] . We can modulate different signal pathways to accumulate NK cells in different tissues and organs, and then direct them to kill tumors in targeted organ. For instance, CBLB502, the agonist of TLR5, not only enhances the NK cell activity, but also mobilizes NK cells to the liver, which make it more important in the treatment of hepatocellular carcinoma [51] . Sphingosine kinase (SPK), its catalytic substrate 1-sphingosine1-phosphate (S1P) and five receptors of S1P (S1P1-5) constitute a complex signal network that plays a key role in regulating the distribution of NK cells and T cells in tissues and blood [52] [53] [54] . For example, the reduction of S1P1 can inhibit T cell migration and keep the latter in lymph node to obtain sufficient time for the interaction with DC, thereby promoting the activation and proliferation of antigen specific T cells. The up-regulation of S1P1 in newly generated effector T cells can make T cells rapidly emigrate from lymph node to effector site. Based on these characteristics, we can use S1P1 agonist such as FTY720 in T cell activation phase or DC tumor vaccine treatment, to prolong the interaction time between T cell and DC, enhancing the effect of tumor vaccine. Alternatively, we can use S1P1 agonists to keep T cell in lymph node in the treatment of lymphoma, producing a relatively targeted killing effect on lymphoma cells.
Recent studies have shown that memory-like NK cells can be produced by pre-activating NK cells combining with cytokines (IL-12, IL-15 and IL-18). These memory-like NK cells have enhanced activity and prolonged survival time in vivo [55, 56] . In this way, we can prepare [57] . Therefore, the proliferation (IL-2, IL-12, IL-15 and IL-18), activation (CD16 antibody, Warfarin, NKG2D ligand and KIR inhibitor) and target organ migration (CBLB502, S1P5 agonist and SDF-1) of NK cells can be achieved through manipulating NK cell membrane receptors, all of which contribute to effective tumor treatment. We also can prepare bispecific antibodies through the combination of CD16 antibody with therapeutic antibody targeting tumor antigen so as to achieve the activation of NK cells and targeted killing of tumor cells. Improving and creating a microenvironment conducive to the survival, proliferation and activation of NK cells are also crucial strategies for enhancing the ability of NK cells to kill tumor cells. Detailed information is listed in the following section about environment modulatory therapy.
Anti-tumor strategies for enhancing tumor-targeted phagocytosis of macrophages
Macrophage is a type of innate immune cell originated from myelomoncytes and has special anti-tumor effects. Different from T cells and NK cells which can kill or destroy tumor cells, macrophages can directly "eat up" tumor cells or their debris and process tumor antigens. Firstly, the processed tumor antigens are submitted to T cells to induce a group of tumor-memory effector T cells. Secondly, the ingested substances of tumor cells will be then given back to the body. In contrast, tumor cells which are largely destroyed by T cells and NK cells may lead to "cytokine release syndrome (CRS)" or "oncolytic response". Therefore, it is of great significance to arouse tumor phagocytosis of macrophages. In one sense, tumor cells have some characteristics similar to macrophages. For instance, tumor cells can directly engulf normal cells or cell debris generated by necrotic normal cells. In this way, the nutrition and energy of normal cells can be "absorbed" by tumor cells whose growth may be accelerated at the expense of body consumption. If macrophages could be aroused for targeted phagocytosis of tumor cells, the energy and substances absorbed by tumor cells may be given back to human body, thus achieving a perfect tumor treatment effect. In addition to phagocytosis, macrophages may also play a role in antigen presenting and in the promotion of inflammatory responses, angiogenesis and tissue healing [58] [59] [60] . Like other immune cells, macrophages have many types of receptors on their surface, including cytokine receptors, scavenger receptors, TLRs, and Fc receptors [61] , which may receive different signals and display different functions. Macrophages have dual effects on tumor growth, which are affected by the signals. Generally, macrophages are classified into two kinds, classically activated (M1) and selectively activated (M2), showing killing and promoting effects on tumor cells, respectively [62] . M1 and M2 may achieve mutual transformation under the impacts of environmental signals.
To arouse tumor-targeted phagocytosis by macrophages, two key problems need to be resolved: how to change the phenotype of tumor cells and then promote the capability of macrophages to recognize and devour them, and how to transform M2 macrophages, namely tumor-associated macrophages (TAM), into tumor-killing M1 macrophages. The followings are some measures to solve these problems. A combined application of anti-tumor antibodies and macrophages mediated by Fc receptors may promote the engulfment effect of macrophages on tumor cells, which is the so-called antibody-dependent cell phagocytosis (ADCP effect). CD47 highly expressed by tumor cells can interact with signal regulatory protein-α (SIRPα) on the surface of macrophages and deliver a "Do not eat me" signal to them to prevent tumor cells from be engulfed [63] . Hence, CD47-targeted antibody can be used to prevent CD47-SIRPα interaction, and then promote the phagocytosis effect of macrophages on tumor cells [64] . Epigenetic drugs [65] , cytoxic drugs [66] , and physical therapies, such as radiotherapy and thermal therapy, can be applied to change the phenotype of tumor cells and expose tumor antigens, thus making macrophages more effectively in recognize and engulf tumor cells. In addition, using the agonists of TLRs or cytokines (IL-2, IFN-gamma, TNF-alpha and histidine-rich glycoprotein) [67] [68] [69] [70] may be another way to promote the transformation of M2 macrophages into M1 type or the tumor phagocytosis.
Anti-tumor strategy via targeting immunosuppressive MDSC and Treg cells
Body's immune system has complicated balance-regulatory mechanisms. To prevent the activation of the immune system, cellular inhibitory receptors and immunosuppressive cells are evolved. That is, a balance among immune cells can be achieved through mutual restriction of inhibitory and activating receptors or different types of immune cells. Tumor cells can intelligently employ these negatively regulatory mechanisms to inhibit anti-tumor immunity of the body. As described above, tumor cells can express ligands to suppress T cells. In addition, tumor cells can also inhibit the activity of effector immune cells by recruiting two important types of immunosuppressive cells, namely specific inhibitory Treg cells [71] and nonspecific myeloid-derived suppressor cells (MDSCs) [72] . Different from Treg cells, MDSCs are a group of nonspecific immature myeloid immune cells [73, 74] . "Birds of a feather flock together", these immature myeloid immune cells are similar to tumor cells in terms of primitiveness and immaturity, and thus can be recruited into tumor tissues to form an immunosuppressive microenvironment favorable for tumor growth. Generally, immunosuppressive effects of these inhibitory immune cells are shown in the following aspects. Firstly, they can cause an inability state of killing T cells through highly expressing arginase1 to decompose L-arginine [75] [76] [77] . Secondly, they generate a large amount of oxygen free radicals that can cause conformational alteration or the disruption of membrane receptors of killing immune cells, leading to ineffective identification of tumor antigens (conformational alteration or disruption of TCR), ineffective activation (conformational alteration or disruption of IL-2R), and/or hindered migration (conformational alteration or disruption of CCR2) [78, 79] . Thirdly, they secrete negative immuneregulatory factors, such as IL-10, and TGF-beta, to inhibit the activity or migratory ability of killing immune cells [80, 81] .
The following anti-tumor strategies may be adopted to target these inhibitory immune cells. The blocking antibody or reagent of such factors as M-CSF can be used to interfere with the CCL2-CCR2 interactions, thus inhibiting the migration of immunosuppressive cells to tumor tissues. Chemical drugs can be applied to kill or remove inhibitory immune cells in tumor microenvironment. Immunoregulatory factors can be assumed to promote the proliferation and activation of killing immune cells. Differentiation inducers can be utilized to induce MDSC maturation, or the means can be taken to improve local environment.
Tumor microenvironment modulatory therapy
The purpose of tumor microenvironment modulatory therapy is to disrupt the microenvironment of tumor tissues and improve body's internal environment, thus generating suitable environment signals for the activation and proliferation of killing immune cells, and providing favorable conditions for stem cells to rapidly repair damaged tissues. Tissue hypoxia, oxidative stress, metabolic disorders, and chronic inflammation are the main characteristics of tumor microenvironment. Tumor microenvironment modulatory therapy refers to treatments directing at these characteristics, as well as improving immune environment via providing a variety of immunoregulatory factors. Traditional Chinese medicine may play an especial role in environment modulatory therapy. It considers the blood stasis as the major etiology of tumorigenesis, and one major approach for tumor treatment is to promote blood circulation and dissipate blood stasis, thus improving local hypoxia. For example, flavonoid as one component of traditional Chinese medicine is a powerful antioxidant that may antagonize local oxidative stress of tumor cells [82, 83] .
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Strategies for correcting hypoxia and oxidative stress
In addition, hypoxia may also be corrected by normalizing abnormal tumor vessels [84] . For rapid growth, tumor cells often secrete a large number of angiogenic growth factors including vascular endothelial growth factor (VEGF), placental growth factor (PIGF) and angiogenin [85, 86] . These factors will promote the abnormal growth of tumor vessels that contribute to the formation of hypoxic microenvironment. In 1970s, Folkman found that the proliferation of tumor cells was achieved through angiogenesis [87] , and inferred that "starving" tumor cells by inhibiting tumor angiogenesis could be one of tumor treatment strategies. Based on this concept, a series of drugs have been designed to inhibit tumor angiogenesis, including bevacizumab (anti-VEGF antibody) and endostar [88, 89] . However, these drugs did not show satisfactory efficacy [90] . This phenomenon may be caused by unreasonable application of the drugs that greatly disrupt tumor vessels, aggravate local tissue hypoxia and destroy local anti-tumor immunity. Damaged tumor vessels can not delivery drugs to tumor sites, thus indirectly assisting the growth and metastasis of tumor cells. Under the treatment with anti-angiogenic drugs, paraplastic vessels of tumors will firstly become normalized (reasonable therapy) and then transform into abnormally atrophy vessels (over-treatment). For instance, a study indicated that anti-angiogenic treatment with bevacizumab for once may transform paraplastic vessels into normalized ones for about 12 days [91] . It is critical to transform tumor vessels into normalized state in anti-angiogenic treatment. To this end, the dosage, intensity, and timing of the treatment should be strictly controlled. The normalization of tumor vessels can alleviate local hypoxia, activate effector immune cells, and make anti-tumor drugs reach tumor sites to increase drug concentration in local positions. Therefore, proper anti-angiogenic treatment should be applied in combination with chemotherapy or anti-tumor immunotherapy [92] .
Treatment strategies for correcting metabolic disorders
Because of hypoxic environment and rapid growth, the local substance metabolism of tumor tissues is in an abnormal state, which manifests as significantly-increased levels and activity of multiple enzymes which mainly consist of those degrading extracellular matrix and participating in the metabolism of glucose, lipid and protein, redox metabolism and the regulation of signaling pathways. In tumor cells, anaerobic glycolysis metabolism occurs under aerobic conditions and two key enzymes pyruvate kinase and alpha enolase involved in this process are abnormal. The pyruvate kinase is M2 subtype in tumor cells, which is different from in normal tissues [93] . Alpha enolase can be ectopically expressed on the cell membrane as the receptor for plasminogen to promote tumor metastasis [94] . Antimetabolite agents such as metformin and glimepiride can be used to correct the abnormal metabolism of tumor cells [95] [96] [97] [98] . Extracellular matrix degrading enzymes or tissue digestive enzymes including urokinase, matrix metalloproteinase, cathepsin, and plasmin can not only promote tumor metastasis by degrading matrixes, but also may destroy antibody or cytokine antitumor drugs. Therefore, controlling the activity of these enzymes may be a useful strategy for tumor treatment and metastasis prevention. An antibody-like molecule has been created via using the extracellular region of tumor endothelial marker 8 (TEM8) and the Fc segment of human IgG1 antibody (TEM8 ext -Fc), which has been shown a powerful anti-tumor activity via inhibiting angiogenesis [99] . Subsequent studies indicate that this protein may block the activity of urokinase. Since a remarkable elevation of urokinase has been observed in multiple tumors, TEM8 ext -Fc may play an important role in preventing the degradation of tumor stroma. Of course, for some tumors with hard texture, anti-fibrosis drugs containing hepatocyte growth factor (HGF) may also be introduced to prevent the formation of tumor stroma, destroy the tumor immunologic barrier, and enhance the effect of antitumor immunotherapy. Dipeptidylpeptidase 4 (DPP4) can not only elevate blood sugar by degrading GLP-1, but also inhibit the migration of killing T cells towards tumor location via degrading CXCL10. Therefore, its inhibitor sitagliptin, a drug for the treatment of metabolic diseases, can significantly improve anti-tumor immunity [100] . As an "energy currency", ATP releases energy through hydrolyzing phosphate radical. The metabolism of tumors is active and needs a lot of energy, leading to a local hypoxia condition and excessive hydrolysis of ATP by CD39 and CD73 overexpressed by Treg cells, which result in the production of large amounts of adenosine [101] [102] [103] . High concentrations of adenosine will then combine with its receptors A2AR and A2BR to inhibit the activation of TCR signals, thus weakening the killing effects of T cells on the tumor, which is known as hypoxia-adenosinergic immunosuppression [104, 105] . In addition, abnormal metabolic enzymes in tumor tissues also include enzymes generating proinflammatory factors or degrading specific amino acids. For example, immunosuppressive cells MDSCs and TAM in tumor tissues can highly express arginase 1 that can degrade L-arginine needed in the activation of killing T cells [75] [76] [77] 106] .
Treatment strategies for controlling chronic inflammation
Tumor microenvironment is complicated and has numerous different types of inflammatory factors. These factors may lead to inflammatory responses such as local edema, pain and fever via stimulating angiogenesis and increasing vascular permeability. Besides, they result in weakened anti-tumor immunity and fastened tumor growth through recruiting immunosuppressive cells. Since inflammatory responses may also resist tumor growth, we should keep good control of anti-inflammatory treatment just as in anti-angiogenic tumor therapy. We propose that precise anti-inflammatory treatment should be conducted on the basis of measured levels of these inflammatory factors. Generally, inflammatory factors can be classified into three classes: cytokines, such as TNF-alpha, IL-6, IL-17A, and IL-1beta; abnormally increased metabolic enzymes or products, such as IDO, NO, and PGE2; and cellular contents released by dead or necrotic cells, such as mitochondrial components and nucleic acid fragments. For the first class, specific blocking antibodies for single inflammatory factor [107] [108] [109] or double-blocking antibodies that can block two inflammatory factors simultaneously may be applied. For the second class, specific enzyme inhibitors for IDO, COX2, and iNOS can be used to inhibit the enzyme activity and reduce the generation of inflammatory metabolites [110] [111] [112] . For the third class, proper measures should be taken to enhance the phagocytosis of macrophages to clean up these cellular contents and relieve inflammatory responses.
Supportive treatment focusing on tissue repairing
Rapid tumor growth and conventional anti-tumor therapies will inevitably cause injuries to the structure and function of normal tissues. In addition, the tumor occurrence is also closely related with tissue injury, because tissue injury activates mutated genes and causes inflammatory responses, which are the essential requirements for tumor occurrence. Once tumor occurs, it will be difficult for the damages on normal tissues to be healed, which is why tumor is considered as an incurable wound [113] . It is revealed that the incidence rate of tumor is closely correlated with age, with an exponential growth among individuals over 40 years old in both women and men [114] . The elderly population has a high incidence rate in developing solid tumors, like lung, liver, and gastrointestinal tumors, so solid tumors have become one of the commonly encountered senile diseases [115] . This phenomenon may be explained by reduced stem cell pool and accordingly decreased ability to repair injured tissues in elderly people. Thus, supportive treatment focusing on tissue repair not only can strengthen body's resistance to invasive tumor therapy, but also represents a key part for curing tumors.
Repairing therapy should consist of tissue repair and nutritional supplement. First of all, gastrointestinal mucous membranes need to be repaired so as to promote food digestion and absorption. Secondly, liver functions should be improved to facilitate metabolism of energy and substances. Thirdly, the functions of heart, lung and kidney should be maintained to improve the insufficiency of both blood and vital energy. Fourthly, hematopoietic and immune systems need to be healed to enhance anti-tumor immunity. Finally, neuropsychology should be rehabilitated via emotion management, pain control and spiritual compensation [116] . Thus, giving psychological guidance and spiritual concern and rational administrating drugs could be recommended, such as antidepressants, anticonvulsants, tranquillizers, agents However, stem cells may also promote tumor growth. Therefore, it is of most importance to prevent tumor growth in repairing therapy using stem cells. We found that mesenchymal stem cells (MSCs) may have two opposite phenotypes of inhibiting and promoting tumor growth. TLR5 positive is one of the major characteristics of the phenotype in inhibiting tumor growth. Therefore, preprocessing or gene-modifying MSCs using TLR5 or the 3TSR segment of thrombospondin-1 combined with S-TRAIL may be a good approach for MSCbased tumor therapy, thus promoting tissue repair and inhibiting tumor growth [118] .
Conclusion and advantages of novel therapeutic strategy
Based on the above elaborations about tumor treatment, we propose a novel strategy for comprehensive treatment of solid tumors, with antibody drug and cell therapeutic technique as the core, in combination with surgery, radiotherapy, chemotherapy. Centered on intrinsic anti-tumor immune mechanism and tissue-repairing system of human body, this strategy will be a integration of considerations on: (1) different types of immune cells and stem cells, including T cells, NK cells, NKT cells, macrophages, hematopoietic stem cells, and mesenchymal stem cells, (2) antibody drugs, such as tumor-targeted, broad-specificity, bispecific, T cell activation, NK cell activation, and macrophage activation antibodies as well as blocking antibodies for inflammatory factors, (3) immunoregulatory factors, including thymosins, interleukins, interferons, lenalidomide, and TLR agonists like CBLB502, and (4) environment modulatory drugs, such as anti-angiogenic agents, antioxidants, antimetabolites, and anti-inflammatory agents. Based on this strategy, a safe, scientific, reasonable, and effective tumor treatment scheme can be made, with the hope that solid tumors can be radically cured in the future.
In general, our novel strategy has four advantages. Firstly, multiple steps of treatment with antibodies and immune cells can induce the generation of anti-tumor memory immune cells or activate the existing ones so as to establish the long-term and systemic anti-tumor immunity. Secondly, multiple measures are crossly applied for all-around targeted clearance of tumor cells in different levels, especially for residual tumor stem cells. Thirdly, the theories of activating blood to remove stasis, eliminating pathogen to thoroughly improve body's internal environment and remove the "soil" that breeds tumor. Lastly, the strategy has the characteristics of both universality, such as improving the body's internal environment and destroying tumor microenvironment, and individualization, like the application of targeted drugs and patient's immune cells.
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